title: Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study.
abstract: The effect of treatment with percutaneous E(2) (100 μg/24 h) during 2 weeks perimenstrually on the number and severity of menstrual migraine attacks was studied in 27 women in a randomized, placebo-controlled, double-blind, crossover trial. We were not able to demonstrate any difference between E(2) supplementation and placebo on the number or severity of migraine attacks, but both regimens showed significant effects compared with before treatment. CLINICAL TRIAL IDENTIFICATION NUMBER: NCT00204074.
authors.affiliation: Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
authors.forename: Anna
authors.initials: A
authors.lastname: Almén-Christensson
authors.forename: Mats
authors.initials: M
authors.lastname: Hammar
authors.forename: Lotta
authors.initials: L
authors.lastname: Lindh-Åstrand
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Landtblom
authors.forename: Jan
authors.initials: J
authors.lastname: Brynhildsen
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008597:Menstrual Cycle; D008881:Migraine Disorders / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D015990:Placebo Effect; D012720:Severity of Illness Index; D013548:Sweden; D013997:Time Factors; D057968:Transdermal Patch; D016896:Treatment Outcome
chemical_list: D004958:Estradiol